Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (4285)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
Jun 15, 2022 (publication date) through Apr 30, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Diabetes
ISSN
1948-9358
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Wang CR, Tsai HW. Immediate-release tofacitinib reduces insulin resistance in non-diabetic active rheumatoid arthritis patients: A single-center retrospective study. World J Diabetes 2022; 13(6): 454-465 [PMID: 35800413 DOI: 10.4239/wjd.v13.i6.454] |
|---|---|
| URL: | https://www.wjgnet.com/1948-9358/full/v13/i6/454.htm |
| Number | Citing Articles |
| 1 |
Seham Abdallah Elazab, Wagenat Effat Elsayed, Nosaiba Mohammed Alrahim, Marwa Abdallah Elsaid, Samah Mohamed Akab, Alshimaa Ahmed Ezzat Mohammed Enayet, Maha Salah Eldin Mohamed, Sherien Abdallah Elazab, Marwa Mostafa Sonbol, Radwa Mohamed Fath Allah. Relationship between Triglyceride-Glucose Index and Disease Activity and
Subclinical Atherosclerosis in Rheumatoid Arthritis. Current Rheumatology Reviews 2024; 20(2): 191 doi: 10.2174/0115733971259984230922054439
|
| 2 |
Chrong-Reen Wang, Wei-Chieh Lin, Tak-Wah Wong. Extended-Release Tofacitinib Therapy for a MDA5 Antibody-Positive Amyopathic Dermatomyositis Patient with Early-Stage Interstitial Lung Disease. ImmunoTargets and Therapy 2023; : 187 doi: 10.2147/ITT.S445971
|
| 3 |
Debora Collotta, Maria Paola Franchina, Virginia Carlucci, Massimo Collino. Recent advances in JAK inhibitors for the treatment of metabolic syndrome. Frontiers in Pharmacology 2023; 14 doi: 10.3389/fphar.2023.1245535
|